Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
9/18/2024 | $85.00 → $70.00 | Buy → Hold | Jefferies | |
7/31/2024 | Neutral → Outperform | Daiwa Securities | ||
7/29/2024 | Underperform → Peer Perform | Wolfe Research | ||
7/25/2024 | $100.00 → $70.00 | Buy → Hold | TD Cowen | |
7/25/2024 | $105.00 → $75.00 | Buy → Neutral | BofA Securities | |
7/25/2024 | $102.00 → $70.00 | Outperform → Neutral | Robert W. Baird | |
7/25/2024 | $105.00 → $72.00 | Overweight → Neutral | JP Morgan | |
7/25/2024 | $110.00 → $82.00 | Buy → Hold | Truist |
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
SC 13G/A - Edwards Lifesciences Corp (0001099800) (Subject)
SC 13G/A - AtriCure, Inc. (0001323885) (Subject)
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
Company announces $1 billion share repurchase Edwards Lifesciences (NYSE:EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE:BDX) for $4.2 billion in an all-cash transaction. The net proceeds from the sale will be used to fund strategic initiatives including the previously announced acquisitions and share repurchases. "Critical Care has made significant contributions to our company and has a long history of innovation. We are grateful to the team for their commitment to improving patient outcomes globally," said Bernard Zovighian, Edwards' CEO. "The sale of Critical Care reflects our sharpened focus as a structural heart
Edwards Lifesciences (NYSE:EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation (TAVI). Presenting one-year results during a Hot Line session at the ESC Congress 2024, investigators reported superior outcomes for women receiving the Edwards SAPIEN 3 Ultra or SAPIEN 3 Ultra RESILIA valves as compared to those receiving surgical aortic valve replacement (SAVR). "Women are an underrepresented group in the diagnosis and treatment of severe aortic stenosis and this landmark study provides important insights into their treatment options," said Hélène Eltchaninoff, M.D., head of
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of AtriCure's AtriClip platform, with ease of use and design simplicity that offers enhanced access and increased visibility for physicians. "The AtriClip FLEX-Mini is an unparalleled product that reinforces our position as the market lea
8-K - Edwards Lifesciences Corp (0001099800) (Filer)
S-8 - AtriCure, Inc. (0001323885) (Filer)
S-8 - Edwards Lifesciences Corp (0001099800) (Filer)
Jefferies downgraded Edwards Lifesciences from Buy to Hold and set a new price target of $70.00 from $85.00 previously
Daiwa Securities upgraded Edwards Lifesciences from Neutral to Outperform
Wolfe Research upgraded Edwards Lifesciences from Underperform to Peer Perform
4 - AtriCure, Inc. (0001323885) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
4 - Edwards Lifesciences Corp (0001099800) (Issuer)
AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck
IRVINE, Calif., Dec. 8, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE:EW) today announced that following regular succession planning discussions with the Board of Directors, Edwards' chairman and CEO, Michael A. Mussallem, who recently turned 70, has informed the Board of his decision to retire as CEO in connection with the company's Annual Meeting of Stockholders on May 11, 2023. At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards' Board. He will be succeeded as CEO by Bernard Zovighian, currently corporate vice pre
AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Citigroup analyst Paul Lejuez downgraded the rating for Lululemon Athletica Inc. (NASDAQ:LULU) from Buy to Neutral, while cutting the price target from $415 to $300. Lululemon shares settled at $272.06 on Wednesday. See how other analysts view this stock. See how other analysts view this stock. Argus Research analyst Kevin Heal downgraded Zions Bancorporation (NASDAQ:ZION) from Buy to Hold. Zions Bancorp shares closed at $50.98 on Wednesday. See how other analysts view this stock. B
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $85 to $70.
Oppenheimer analyst Suraj Kalia maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $100 to $90.
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 financial results. "Our second quarter results reflect strong growth worldwide, underscored by our pain management and open AtriClip® franchises, as we continued to deliver exceptional patient outcomes across all therapies, while driving positive cash flow," said Michael Carrel, President and Chief Executive Officer at At
Edwards Lifesciences (NYSE:EW) today reported financial results for the quarter ended June 30, 2024. Highlights and Outlook Q2 sales grew 7%; constant currency1 sales grew 8% Q2 TAVR sales grew 5%; constant currency1 sales grew 6% Q2 TMTT sales grew 75%; increasing contribution to Edwards' growth Q2 EPS of $0.61; adjusted1 EPS of $0.70 Significant TAVR and TMTT clinical evidence to be presented at TCT in October 2024 Positive EVOQUE introduction with excellent patient outcomes; NCD process on track Critical Care sale expected to close late Q3 2024 Expect full-year 2024 Edwards sales growth of 8 to 10%; lowering TAVR guidance to 5 to 7% from 8 to 10%; increasing TMT
Edwards Lifesciences (NYSE:EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives t